Global Leukemia Academy

Emerging and Practical Concepts and Controversies in Leukemias

Overview

In recent years progress in the molecular understanding of acute leukemias has led to greatly improved comprehension of these diseases, and novel approved therapies are changing treatment paradigms. Aptitude Health has developed the Global Leukemia Academy and is organizing a series of meetings in 2020 to help physicians better understand how the emerging therapies and concepts are being adapted globally, and to address barriers between innovation and implementation for patient care.

Date and Location

23–24 October 2020
Virtual Meeting

Meeting Content

View the slides and watch the video of the Day 1
ALL Plenary Session

View the slides and watch the video of the Day 2
ALL Adult Session

View the slides and watch the video of the Day 2
ALL Pediatric Session

Faculty

Patrick Brown

Patrick A. Brown, MD

Johns Hopkins University School of Medicine, USA

Dieter Hoelzer

Dieter Hoelzer, MD, PhD

University of Frankfurt,
Germany

Elias Jabbour

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, USA
(Meeting Chair)

Franco Locatelli

Franco Locatelli, MD, PhD

University of Rome
IRCCS Ospedale Pediatrico
Bambino Gesù, Italy
(Meeting Chair)

Rob Pieters

Rob Pieters, MD, PhD

Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands

Josep Ribera

Josep Ribera, MD

Catalan Institute of
Oncology, University
Hospital Germans Trias i
Pujol, Spain

Philippe Rousselot

Philippe Rousselot, MD, PhD

University of Versailles Saint-Quentin-en-Yvelines,
France

Agenda

The virtual program was held over 2 days with 3 sessions as follows.
Day 1: Plenary Session ALL
Day 2: Parallel breakout sessions – Adult ALL and Pediatric
DAY 1:
Virtual Plenary sessions
Time, CET Title Speaker
Friday, 23 October 2020 from 16.00 – 20.00 CET 16.00 – 16.10 Welcome and overview
• Introduction to the voting system
Elias Jabbour,
Franco Locatelli
  16.10 – 16.25 Review of prognostic value of MRD in ALL Elias Jabbour
  16.25 – 16.40 How and when to check for MRD in ALL, including CR1 and CR2 Josep-Maria Ribera
  16.40 – 16.55 Genetic variants in ALL – Ph+ and Ph-like Philippe Rousselot
  16.55 – 17.15 AYA ALL patients – what is the current treatment approach for this diverse patient population? Rob Pieters
  17.15 – 17.40 Bispecific T-cell engagers as post-reinduction therapy improves survival in pediatric and AYA B-ALL Patrick Brown
  17.40 – 18.00 Break  
  18.00 – 18.45 Panel discussion on the role of HSCT
• Role of transplant in MRD+ population
• Role of transplant in Salvage Setting
• Discussion and voting
Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer
Philippe Rousselot,
Josep-Maria Ribera
  18.45 – 19.25 Debate on CD19-targeted approaches
• CAR T
• Bispecifics
• Discussion and voting
Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer
Josep-Maria Ribera,
Elias Jabbour
  19.25 – 19.55 Emerging data and the management of ALL patients during COVID-19
• Presentation
• Panel discussion
Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer
Elias Jabbour
  19.55 – 20.00 Session close Elias Jabbour, Franco Locatelli

 

DAY 2:
Virtual Breakout 1: Adult ALL patients
Time, CET Title Speaker
  18.00 – 18.15 Session open
• Educational ARS questions for the audience
Elias Jabbour
  18.15 – 18.35 Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens
•Presentation
• Q&A
Elias Jabbour
  18.35 – 18.55 Current treatment options for relapsed ALL in adult and elderly patients
• Presentation
• Q&A
Dieter Hoelzer
  18.55 – 19.45 Case-based panel discussion
Management of long- and short-term toxicities and treatment selection in adult and elderly patients
• Case 1
• Case 2
• Discussion
Faculty panel: E. Jabbour, D. Hoelzer, J.M. Ribera, P. Rousselot
Philippe Rousselot,
Josep-Maria Ribera
  19.45 – 20.00 Session close
• Educational ARS questions for the audience
Elias Jabbour

 

DAY 2:
Virtual Breakout 2: Pediatric ALL patients
Time, CET Title Speaker
Saturday, 24 October 2020 from 18.00 – 20.30 CET 18.00 – 18.15 Session open
• Educational ARS questions for the audience
Franco Locatelli
  18.15 – 18.45 First-line treatment of pediatric ALL
• Presentation
• Q&A
Rob Pieters
  18.45 – 19.15 Current treatment options for relapsed ALL in children, including HSCT and COVID-19 considerations
• Presentation
• Q&A
Franco Locatelli
  19.15 – 19.45 Bispecific T-cell engagers for pediatric ALL
• Presentation
• Q&A
Patrick Brown
  19.45 – 20.15 Case-based panel discussion
Management of long- and short-term toxicities and treatment selection in pediatric patients
• Case 1
• Case 2
• Discussion
Faculty panel: R. Pieters, F. Locatelli, P. Brown
Rob Pieters
Patrick Brown
  20.15 – 20.30 Session close
• Educational ARS questions for the audience
Franco Locatelli